Susquehanna International Group’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-34,103
Closed -$155K 13987
2025
Q4
$190K Buy
34,103
+7,900
+30% +$87.9K ﹤0.01% 10931
2025
Q3
$193K Buy
26,203
+21,358
+441% +$182K ﹤0.01% 11031
2025
Q2
$36.9K Sell
4,845
-6,728
-58% -$105K ﹤0.01% 12196
2025
Q1
$221K Buy
11,573
+1,472
+15% +$46.3K ﹤0.01% 10738
2024
Q4
$366K Buy
10,101
+6,943
+220% +$193K ﹤0.01% 9386
2024
Q3
$91K Buy
3,158
+1,107
+54% +$24.6K ﹤0.01% 11106
2024
Q2
$52.5K Sell
2,051
-10,082
-83% -$458K ﹤0.01% 11393
2024
Q1
$917K Buy
12,133
+1,847
+18% +$146K ﹤0.01% 7109
2023
Q4
$1.06M Buy
+10,286
New +$923K ﹤0.01% 6856
2023
Q2
Sell
-3,655
Closed -$463K 12987
2023
Q1
$306K Sell
3,655
-922
-20% -$80.5K ﹤0.01% 9675
2022
Q4
$389K Buy
4,577
+966
+27% +$73.7K ﹤0.01% 8457
2022
Q3
$115K Buy
+3,611
New +$99.8K ﹤0.01% 11568
2022
Q2
Sell
-1,565
Closed -$54.8K 13806
2022
Q1
$77K Buy
1,565
+146
+10% +$5.83K ﹤0.01% 12074
2021
Q4
$80K Buy
1,419
+87
+7% +$6.2K ﹤0.01% 12287
2021
Q3
$108K Buy
+1,332
New +$105K ﹤0.01% 12026

Other funds holding RVPH

Susquehanna International Group's RVPH Position: Q1 2026 in Review

Susquehanna International Group sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q1 2026, closing a stake of 34,103 shares — an estimated $155K sold.

Susquehanna International Group first reported a position in RVPH in Q3 2021 and held it in 15 quarters. The position peaked at $1.06M in Q4 2023. 35 funds tracked by Wall St. Rank hold RVPH as of Q1 2026.

  • Susquehanna International Group reported no remaining REVIVA PHARMA HLDGS INC position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 34,103 REVIVA PHARMA HLDGS INC shares in Q1 2026, an estimated $155K.
  • Susquehanna International Group first reported a position in REVIVA PHARMA HLDGS INC in Q3 2021 and held it in 15 quarters.
  • Susquehanna International Group's REVIVA PHARMA HLDGS INC position peaked at $1.06M in Q4 2023.
  • 35 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.